These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
714 related articles for article (PubMed ID: 32561648)
1. Tan J; Liu R; Zhu G; Umbricht CB; Xing M Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648 [TBL] [Abstract][Full Text] [Related]
2. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
4. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Li Y; Cheng HS; Chng WJ; Tergaonkar V Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794 [TBL] [Abstract][Full Text] [Related]
5. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459 [TBL] [Abstract][Full Text] [Related]
6. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. Wang H; Quan H; Lou L Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078 [TBL] [Abstract][Full Text] [Related]
7. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159 [TBL] [Abstract][Full Text] [Related]
8. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF Zeng Q; Deng Y; Zhang L; Wang W Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623 [TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281 [TBL] [Abstract][Full Text] [Related]